Trabectedin: safety and efficacy in the treatment of advanced sarcoma - Wikidata - wikimedia - TriplyDB

Trabectedin: safety and efficacy in the treatment of advanced sarcoma

Trabectedin: safety and efficacy in the treatment of advanced sarcoma

http://www.wikidata.org/entity/Q34628607

about

Alkaloids from marine invertebrates as important leads for anticancer drugs discovery and development Emerging therapies for adult soft tissue sarcoma.A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.Uterine leiomyosarcoma manifesting as a tricuspid valve mass.Cytotoxic and antioxidant marine prenylated quinones and hydroquinones.Molecular targeted therapy in gynaecologic malignancies: primer for radiologists.Managing sarcoma: where have we come from and where are we going?

P2860

Q27012072-9F996A0C-B517-4BC1-8C76-F55D8291746F Q34659806-511262D1-2DFB-4725-9FC7-399DA83A2A1A Q35246995-FCDFD1DE-D590-4469-8669-136810456E5C Q36744460-C0E3B04D-D8A2-49A6-8C0F-A270A5DD5AEE Q37989851-22B814EA-9E56-44B2-A941-0F8E67262D62 Q38849896-0C2E81BE-0ABD-40EB-BD82-ACCC93D0DC57 Q41988197-55E158CC-7400-47F7-9DF3-754C6C805C7F

P2860

Trabectedin: safety and efficacy in the treatment of advanced sarcoma

http://www.wikidata.org/entity/Q34628607

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Trabectedin: safety and efficacy in the treatment of advanced sarcoma

@ast

Trabectedin: safety and efficacy in the treatment of advanced sarcoma

@en

Trabectedin: safety and efficacy in the treatment of advanced sarcoma

@nl

type

label

Trabectedin: safety and efficacy in the treatment of advanced sarcoma

@ast

Trabectedin: safety and efficacy in the treatment of advanced sarcoma

@en

Trabectedin: safety and efficacy in the treatment of advanced sarcoma

@nl

prefLabel

Trabectedin: safety and efficacy in the treatment of advanced sarcoma

@ast

Trabectedin: safety and efficacy in the treatment of advanced sarcoma

@en

Trabectedin: safety and efficacy in the treatment of advanced sarcoma

@nl

P1433

Q34628607-654A8D65-137E-47D7-B762-C4B2C1E67083

P1476

Q34628607-85B6556F-7E46-42AD-9C2D-3943A5F72B8D

P2093

Q34628607-043AC3C7-449C-4A4F-BA8E-7C9C3346C003

Q34628607-2A63D364-3E4A-4468-B6E4-383EEBA9B597

P2860

Q34628607-0455F64D-EDDD-40C0-9564-F013A081D230

Q34628607-0D40736D-2B16-4FC5-BBAC-BB8AC3EA47D8

Q34628607-12CFA1D1-E2DC-4E8D-8B3E-09CA2F2E0F0E

Q34628607-1E3DD50F-316D-4F47-BE32-5D42E12E59D6

Q34628607-22F36822-9DF7-47BE-9855-48335081854A

Q34628607-2B6EBA4A-447A-4567-8138-F91F0A302D4D

Q34628607-380D9E9C-1E64-4ABF-9B37-329A4F58524F

Q34628607-3951D05D-0408-4D2E-B4F0-F216DCA10A7C

Q34628607-51E12799-0FDE-494B-AB87-1D22A5A18307

Q34628607-5CD71B18-CA6A-4FD7-B0B0-DA0F714B0104

P304

Q34628607-EE7A30A2-E4BA-4F1A-A9D3-2513CE216A9E

P31

Q34628607-2ACE44AF-D54F-4A11-9F2A-4952A6C0A74A

P356

Q34628607-47B44896-1F50-4479-A1B8-99CD107FE33B

P407

Q34628607-5DDF49CB-ED2F-4156-8A04-6520D689BFC1

P478

Q34628607-39081301-995B-4768-B020-C1E084EE375D

P577

Q34628607-DBB934AE-9424-4304-8B27-06BE768CDCBE

P5875

Q34628607-D914639D-8E51-42E1-A8B1-1CAC86F30EEC

P698

Q34628607-73C0210F-B1BF-4CEE-B30A-D0D885695F90

P921

Q34628607-8705AE85-A902-4EE8-A025-8AEE05A6B4C0

P932

Q34628607-AFF958B3-1927-4C6E-B7B7-FB2B4B440F08

P356

P1433

Clinical Medicine: Oncology

P1476

Trabectedin: safety and efficacy in the treatment of advanced sarcoma

@en

P2093

Anthony Elias

http://www.w3.org/2001/XMLSchema#string

Csaba Gajdos

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the management of soft tissue sarcomas

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.

P304

35-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/CMO.S4907

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51057396

http://www.w3.org/2001/XMLSchema#string

P698

21499557

http://www.w3.org/2001/XMLSchema#string

P921

P932

3076042

http://www.w3.org/2001/XMLSchema#string